Replies to post #219971 on Biotech Values

[biocqr]

M Shkrelli on ACAD...

http://martinshkreli.com/

Acadia. I still don’t think this drug will ever sell too much. There are a few D2 sparing 5-HT2a antagonists (nothing as pure as pimavanserin, given), but the company’s spending is a bit insane. The drug is probably great for PDP given the levodopa interference at the dopamine receptor, but what good is the drug for the other illnesses when you can use Risperdal, Abilify, Seroquel, etc. Re spending, I understand that one needs to invest in a brand, and it will stop at some point, but this is quite dramatic cash use. I am skeptical of the intellectual property of pima, so I expect a generic sooner than others.

[semi_infinite]

He is just the messenger as Cohodes is the owner of those articles apparently. I don't know if Nuplazid will be a huge success, it works very well for some and it may not do any better than off label anti-depressants in some. But the big lie is that it is less safe than off label use of existing meds. My observation from visits to nursing and assisted living situations are that doctors don't have good choices and often times prescribe a cocktail of off label meds for these PD patients without proper monitoring of whether the meds are doing any good or making the patient worse. One case I am familiar with showed that off label meds just turned the patient into a zombie. Great, no hallucinations, no life either.